Leidos' Healthcare Business Sees Limited Future Upside From Increasing Competition, BofA Securities Says

MT Newswires Live

06/17

Leidos' (LDOS) healthcare business sees limited future upside from increasing competition, BofA Securities said in a Wednesday note.

BofA said it sees near-term pressure on the healthcare business as the U.S. Defense Health Agency seeks to work directly with suppliers in the Defense Health Management System Modernization program's maintenance phase.

It also said the upcoming Medical Disability Examinations recompete could weigh on Leidos' future share and pricing power.

The investment banking firm said it continues to recognize the value of Leidos' defense portfolio, but added that it does not believe investors will give credit for full value of the opportunities until the results begin to materialize.

BofA downgraded Leidos to neutral from buy and adjusted its price target to $125 from $200.

Price: 110.13, Change: -3.45, Percent Change: -3.04

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2644742103"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644742103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644742103?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644742103","market":"sg","top_or_hot":-1,"title":"Leidos' Healthcare Business Sees Limited Future Upside From Increasing Competition, BofA Securities Says","media":"MT Newswires Live","content":"<html><body><p> Leidos' (LDOS) healthcare business sees limited future upside from increasing competition, BofA Securities said in a Wednesday note.</p><p>BofA said it sees near-term pressure on the healthcare business as the U.S. Defense Health Agency seeks to work directly with suppliers in the Defense Health Management System Modernization program's maintenance phase.</p><p>It also said the upcoming Medical Disability Examinations recompete could weigh on Leidos' future share and pricing power.</p><p>The investment banking firm said it continues to recognize the value of Leidos' defense portfolio, but added that it does not believe investors will give credit for full value of the opportunities until the results begin to materialize.</p><p>BofA downgraded Leidos to neutral from buy and adjusted its price target to $125 from $200.</p><p>Price: 110.13, Change: -3.45, Percent Change: -3.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leidos' Healthcare Business Sees Limited Future Upside From Increasing Competition, BofA Securities Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeidos' Healthcare Business Sees Limited Future Upside From Increasing Competition, BofA Securities Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-17 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Leidos' (LDOS) healthcare business sees limited future upside from increasing competition, BofA Securities said in a Wednesday note.</p><p>BofA said it sees near-term pressure on the healthcare business as the U.S. Defense Health Agency seeks to work directly with suppliers in the Defense Health Management System Modernization program's maintenance phase.</p><p>It also said the upcoming Medical Disability Examinations recompete could weigh on Leidos' future share and pricing power.</p><p>The investment banking firm said it continues to recognize the value of Leidos' defense portfolio, but added that it does not believe investors will give credit for full value of the opportunities until the results begin to materialize.</p><p>BofA downgraded Leidos to neutral from buy and adjusted its price target to $125 from $200.</p><p>Price: 110.13, Change: -3.45, Percent Change: -3.04</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644742103","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644742103","pubTimestamp":1781708063,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Leidos'  healthcare business sees limited future upside from increasing competition, BofA Securities said in a Wednesday note.BofA said it sees near-term pressure on the healthcare business as the U.S. Defense Health Agency seeks to work directly with suppliers in the Defense Health Management System Modernization program's maintenance phase.It also said the upcoming Medical Disability Examinations recompete could weigh on Leidos' future share and pricing power.The investment banking firm said it continues to recognize the value of Leidos' defense portfolio, but added that it does not believe investors will give credit for full value of the opportunities until the results begin to materialize.BofA downgraded Leidos to neutral from buy and adjusted its price target to $125 from $200.Price: 110.13, Change: -3.45, Percent Change: -3.04","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","HCSG":"Healthcare Svcs Group Inc","BK4581":"高盛持仓","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LDOS":"Leidos Holdings Inc","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","XBI":"SPDR S&P Biotech ETF","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4137":"综合支持服务","XLV":"健康照护类股ETF-SPDR","BK4585":"ETF&股票定投概念","BK4123":"调查和咨询服务","BK4588":"碎股"},"translate_title":"美国银行证券表示，Leidos的医疗保健业务未来因竞争加剧而上涨空间有限","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"LABU":0.6,"HCSG":1.5,"LDOS":1.5,"XBI":0.6},"content_text":"Leidos' (LDOS) healthcare business sees limited future upside from increasing competition, BofA Securities said in a Wednesday note.BofA said it sees near-term pressure on the healthcare business as the U.S. Defense Health Agency seeks to work directly with suppliers in the Defense Health Management System Modernization program's maintenance phase.It also said the upcoming Medical Disability Examinations recompete could weigh on Leidos' future share and pricing power.The investment banking firm said it continues to recognize the value of Leidos' defense portfolio, but added that it does not believe investors will give credit for full value of the opportunities until the results begin to materialize.BofA downgraded Leidos to neutral from buy and adjusted its price target to $125 from $200.Price: 110.13, Change: -3.45, Percent Change: -3.04","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}